Mike Rawling

Mike Rawling is an Associate Director of Medicinal Chemistry with extensive experience in biotech, specializing in small molecule drug discovery across various therapeutic areas, including oncology and neurology. With a PhD in Organic Chemistry, Mike has contributed significantly to the development of pre-clinical candidates and successful drug repurposing, notably aiding the FDA approval of baricitinib for COVID-19 treatment. Prior to their current role at Transition Bio, Mike held leadership positions at BenevolentAI and Proximagen, where they led multidisciplinary teams and drove multiple successful drug development initiatives, showcasing a strong record of pitching collaborations worth substantial investments. Mike's expertise is also reflected in their authorship of pivotal publications, including BenevolentAI's first clinical candidate disclosure paper.